• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	CERO THERAPEUTICS HOLDINGS, INC. (CERO)
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date		2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31				2023-Dec-31
Fiscal Period		Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024				Q4-FY2023
Total Revenue							447,335$
QoQ%
YoY%
Cost Of Revenue							0$
Gross Profit							447,335$
Gross Margin							100.00%
Operating Expenses		4,362,579$	4,723,791$	4,950,531$		4,402,238$	5,148,237$		1,121,173$	1,535,571$	2,413,746$	2,438,346$
Operating Income		(4,362,579$)	(4,723,791$)	(4,950,531$)		(4,402,238$)	(5,148,237$)		(1,121,173$)	(1,535,571$)	(2,413,746$)	(2,438,346$)
Operating Margin							(1,150.87%)
Interest Income		5,936$	13,776$	850$		4,418$	0$
Interest Expenses		0$	0$	0$		0$	16,977$					(16$)
Income Before Tax		(4,856,395$)	(5,417,315$)	(5,105,931$)		(4,227,967$)	(2,448,654$)		(1,265,182$)	(1,349,347$)	(2,092,507$)	(2,438,330$)
Tax Expenses
Net Income		(4,856,395$)	(5,417,315$)	(5,105,931$)		(4,227,967$)	(2,448,654$)		(1,265,182$)	(1,349,347$)	(2,092,507$)	(2,438,330$)
Profit Margin							(547.39%)
TTM
Earnings to Minority		6,649,828$	24,700,374$	348,227$
Earnings to Common Shareholders		(11,506,223$)	(30,117,689$)	(5,454,158$)		(4,227,967$)	(2,448,654$)		(1,265,182$)	(1,349,347$)	(2,092,507$)	(2,438,330$)
QoQ%		61.80%	(452.20%)			(72.67%)			6.24%	35.52%	14.18%
YoY%		(172.15%)	(1,129.97%)			(213.33%)	(17.02%)
Earnings Per Share, Basic		(9.10$)	(61.71$)	(1.59$)		(170.22$)	(302.34$)		0.05$	(0.15$)	(0.23$)	(0.27$)
Earnings Per Share, Diluted		(9.10$)	(61.71$)	(1.59$)		(170.22$)	(302.34$)		0.05$	(0.15$)	(0.23$)	(0.27$)
Unlevered FCF Per Share, Basic
Unlevered FCF Per Share, Diluted
Average Shares, Basic		1,264,884	488,076	3,427,616		24,838	8,099		-27,168,656	9,068,899	9,063,377	9,059,732
Average Shares, Diluted		1,264,884	488,076	3,427,616		24,838	8,099		-27,168,656	9,068,899	9,063,377	9,059,732
EBIT		(4,856,395$)	(5,417,315$)	(5,105,931$)		(4,227,967$)	(2,431,677$)		(1,265,182$)	(1,349,347$)	(2,092,507$)	(2,438,346$)
EBITDA		(4,856,395$)	(5,417,315$)	(5,105,931$)		(4,227,967$)	(2,431,677$)		(1,265,182$)	(1,349,347$)	(2,092,507$)	(2,438,346$)

Copy Table ✓